Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$8.18 - $10.78 $346,954 - $457,233
42,415 New
42,415 $399,000
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $558,467 - $735,993
13,698 New
13,698 $637,000
Q1 2021

May 17, 2021

SELL
$41.69 - $54.95 $7.39 Million - $9.74 Million
-177,288 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$41.16 - $47.47 $2.33 Million - $2.68 Million
-56,532 Reduced 24.18%
177,288 $7.46 Million
Q3 2020

Nov 16, 2020

BUY
$43.36 - $53.53 $2.75 Million - $3.4 Million
63,496 Added 37.28%
233,820 $10.7 Million
Q2 2020

Aug 14, 2020

SELL
$46.37 - $57.58 $1.22 Million - $1.51 Million
-26,281 Reduced 13.37%
170,324 $8.55 Million
Q1 2020

May 15, 2020

SELL
$40.22 - $62.0 $4.16 Million - $6.42 Million
-103,480 Reduced 34.48%
196,605 $10.1 Million
Q4 2019

Feb 18, 2020

BUY
$57.95 - $66.61 $239,391 - $275,165
4,131 Added 1.4%
300,085 $18.5 Million
Q3 2019

Nov 14, 2019

BUY
$60.08 - $88.17 $11.5 Million - $16.8 Million
190,743 Added 181.3%
295,954 $17.8 Million
Q2 2019

Aug 14, 2019

BUY
$81.3 - $97.35 $2.77 Million - $3.32 Million
34,100 Added 47.95%
105,211 $8.88 Million
Q1 2019

May 15, 2019

BUY
$69.08 - $105.66 $2.7 Million - $4.12 Million
39,023 Added 121.61%
71,111 $6.79 Million
Q4 2018

Feb 14, 2019

SELL
$65.41 - $84.65 $2.38 Million - $3.08 Million
-36,329 Reduced 53.1%
32,088 $2.27 Million
Q3 2018

Nov 14, 2018

SELL
$85.46 - $126.37 $5.12 Million - $7.57 Million
-59,900 Reduced 46.68%
68,417 $5.85 Million
Q2 2018

Aug 14, 2018

SELL
$81.85 - $120.51 $12.1 Million - $17.8 Million
-147,425 Reduced 53.46%
128,317 $14.9 Million
Q1 2018

May 15, 2018

BUY
$57.91 - $92.15 $16 Million - $25.4 Million
275,742 New
275,742 $22.3 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $109M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.